rais hand share buy-back
go go twice
revenu in-lin ep impact one-tim item
report revenu in-lin consensu
adjust ep miss consensu higher expect sg
 expens sale neg impact expens relat
hurrican maria howev concern amgn profit
compani re-affirmed oper margin enbrel sale beat
consensu neulasta sale came consensu
high end revenu guidanc shi consensu
think manag conserv midpoint ep guidanc
consensu thank updat tax rate
adjust non-gaap ep accordingli maintain po
multipl in-lin major pharma peer reiter buy rate
addit exist share repurchas author announc
share repurchas dutch auction expect repurchas
full author amount correspond outstand share
note conduct dutch auction repurchas
outstand share time stock price appreci auction period
view investor like welcom share purchas
plenti firepow left
gener free cash flow held year end despit
share buy-back believ plenti firepow left acquisit
right opportun aris cash balanc buy-back allow
flexibl pursu extern asset bring mid-to-high singl digit
revenu growth believ think stock command higher price-to-earnings multipl
scenario addit amgn early-to-mid stage pipelin start show
promis anti-tslp phase mutein phase bite bispecif t-cell
engag antibodi program hematolog solid tumor gener clinic data
next month believ investor start appreci potenti
asset
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base belief
consensu revenu estim overestim
impact price pressur competit
top line addit new product
launch anticip biosimilar launch
help drive top-lin growth potenti
repatri signific portion
cash held oversea open door
potenti share buyback dividend payment
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer current trade
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
